echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The Lancet: The third shot of a different type of new crown vaccine is better

    The Lancet: The third shot of a different type of new crown vaccine is better

    • Last Update: 2022-05-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Chilean researchers presented new results of Chile's COVID-19 vaccination program at the European Congress of Clinical Microbiology and Infectious Diseases (Lisbon, Portugal, 23-26 April)


    The research results were also published in The Lancet Global Health on April 23, 2022


    The study evaluated the efficacy of the CoronaVac (Kexing Bio), AZD1222 (Oxford/AstraZeneca) and BNT162b2 (Pfizer/BioNTech) vaccine boosters in individuals who had completed two doses of the Corona vaccine


    The researchers evaluated individuals who were vaccinated between February 2, 2021, and November 10, 2021, while excluding individuals who had been infected with the new coronavirus or who had been vaccinated before that time


    A total of 11.


    The authors calculated that the two-dose vaccine plus the Kexing booster was 79% effective in preventing symptomatic COVID-19, the BNT162b2 booster was 97% effective, and the AZD1222 booster was 93% effective


    The authors explain that booster programs have been launched in countries because of emerging evidence of weakened immunity with the two-dose regimen


    They concluded: "Our results suggest that a third booster dose provides high levels of protection against COVID-19, including severe illness and death, in a population previously vaccinated with two doses of Sinovac vaccine.


    The authors further explain that this is one of the first studies to examine the effectiveness of booster shots of an inactivated SARS-CoV-2 vaccine


    A Cov-Boost study in a phase 2 clinical trial in the United Kingdom showed that after two doses of AZD1222 and BNT162b2 vaccinations, various vaccines were safe and immunogenic as boosters, and antibody levels after mRNA boosters were administered.


    In Chile, the government now recommends that heterologous boosters be preferred; however, homologous boosters can be administered as an alternative


    Original text retrieval

    Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.